Literature DB >> 11803263

The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer.

Kelly J Cude1, Jeffrey S Montgomery, Douglas K Price, Shannon C Dixon, Randall L Kincaid, Karl F Kovacs, David J Venzon, David J Liewehr, Margaret E Johnson, Eddie Reed, William D Figg.   

Abstract

The androgen receptor plays a major role in the development and function of normal and malignant prostate cells. Due to the relationship of the androgen receptor and prostatic growth, it has been proposed that polymorphisms within the androgen receptor may play a role in an individual's susceptibility to developing prostate cancer. An inverse relationship has been established between a highly polymorphic trinucleotide repeat located in the first exon of the androgen receptor and the transactivaton function of the receptor. Serum samples were collected from 131 patients with histologically confirmed adenocarcinoma of the prostate, DNA was isolated, and the polymorphic CAG repeat was amplified by PCR and sequenced. The CAG repeat lengths were then compared with age at diagnosis, age at time of study, baseline log(10) PSA, Gleason score, time from diagnosis to initiation of hormonal therapy, time to progression after androgen ablation, and overall survival time. No correlation was found between CAG length and time to progression or overall survival time, but a significant correlation was found between Gleason score and CAG length suggesting that shorter CAG lengths may predict a higher histological grade of prostate cancer. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11803263     DOI: 10.1159/000048412

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  6 in total

1.  Decision tree-based modeling of androgen pathway genes and prostate cancer risk.

Authors:  Jill S Barnholtz-Sloan; Xiaowei Guan; Charnita Zeigler-Johnson; Neal J Meropol; Timothy R Rebbeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-04-14       Impact factor: 4.254

2.  Amplification and protein expression of androgen receptor gene in prostate cancer cells: Fluorescence in situ hybridization analysis.

Authors:  Xian Zhang; Shi-Zhe Hong; Er-Jiang Lin; DA-Ya Wang; Zhi-Jia Li; L I Chen
Journal:  Oncol Lett       Date:  2015-04-14       Impact factor: 2.967

3.  Influence of short polyglutamine tracts and p160 coactivators on the transactivation of the androgen receptor.

Authors:  Xu-Bao Shi; Lingru Xue; Donghua Shi; Ralph W deVere White
Journal:  Cancer Biother Radiopharm       Date:  2011-04       Impact factor: 3.099

4.  Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.

Authors:  Douglas K Price; Cindy H Chau; Cathee Till; Phyllis J Goodman; Caitlin E Baum; Sandy B Ockers; Bevin C English; Lori Minasian; Howard L Parnes; Ann W Hsing; Juergen K V Reichardt; Ashraful Hoque; Catherine M Tangen; Alan R Kristal; Ian M Thompson; William D Figg
Journal:  J Urol       Date:  2010-10-16       Impact factor: 7.450

5.  Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.

Authors:  Bin Liu; Fraser Conrad; Audrey Roth; Daryl C Drummond; Jeff P Simko; James D Marks
Journal:  J Mol Med (Berl)       Date:  2007-06-07       Impact factor: 4.599

Review 6.  Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes.

Authors:  Charnita M Zeigler-Johnson; Elaine Spangler; Mohamed Jalloh; Serigne M Gueye; Hanna Rennert; Timothy R Rebbeck
Journal:  Can J Urol       Date:  2008-02       Impact factor: 1.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.